Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2022-09-08 Director's Dealing
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
Correction: PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 98% confidence The document is a 'Mandatory notification regarding trade of shares' involving a related party (board member Hilde Furberg) and details a purchase of shares by Borkenholm AS. This directly relates to personal share transactions by company directors or their related parties, which falls under the definition of Director's Dealing (DIRS). Although it mentions MAR regulation, the core content is insider trading disclosure.
2022-09-08 English
PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification regarding trade of shares' involving a related party to a board member (Hilde Furberg). This type of filing reports personal share transactions by company directors or closely associated parties. This directly matches the definition for Director's Dealing (DIRS). The document length is very short (587 chars), but the content is a direct disclosure of a transaction, not an announcement of a separate report, making DIRS the most specific fit over the general RNS.
2022-09-08 English
PCI Biotech interim first-half year 2022 results
Interim / Quarterly Report Classification · 19% confidence
2022-08-31 English
PCI Biotech interim first-half year 2022 results
Interim / Quarterly Report Classification · 100% confidence The document is a 'Second Quarter and First Half-Year Report' for PCI Biotech. It contains detailed financial tables (Key figures for 1H and Q2), an operational review, pipeline updates, and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2022
2022-08-31 English
PCI Biotech interim first-half year 2022 results
Earnings Release Classification · 100% confidence The document explicitly states it announces the "interim first-half year 2022 results" and mentions that the "interim report and the presentation will also be available". This structure—an announcement summarizing key highlights (corporate changes, trial terminations, financial runway) and referencing an enclosed/attached report for the full details—is characteristic of an Earnings Release (ER) or an Interim Report (IR). Since the document covers a period shorter than a year ("first-half year 2022") and provides comprehensive operational and financial context (even if brief), it aligns best with the definition of an Interim / Quarterly Report (IR). While it functions as an ER by announcing results, the content suggests it is the primary vehicle for the period's comprehensive update, making IR the more precise fit than ER (which is usually just the key numbers). The mention of the 'Event title: PCI Biotech Holding Half-yearly Report' further confirms this is the release associated with the interim report. H1 2022
2022-08-31 English
PCI Biotech: Invitation to first-half year 2022 results presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation to a presentation regarding the company's 'first-half year 2022 interim report'. It explicitly states that the interim report will be released on August 31, 2022, and that the presentation will follow. Since the document's primary purpose is to announce the upcoming release of the report and invite stakeholders to the presentation/webcast, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim Report (IR) itself, nor is it the Earnings Release (ER) which typically contains the key figures immediately. The document length (2934 chars) is short, supporting the RPA classification over the full report classification.
2022-08-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.